Table 2.
Mixed Model Parameter Estimates for the Prediction of HAM-D Symptom Reduction Across Treatment (n = 224)
| Estimate | SE | t | Significance | 95% CI Lower |
95% CI Upper |
d | |
|---|---|---|---|---|---|---|---|
| Intercept1 | 14.72 | .39 | 38.05 | p <.001 | 13.96 | 15.48 | 3.60 |
| Gender | −.30 | .46 | .65 | p =.52 | −1.20 | .60 | .06 |
| Age | −.04 | .02 | 1.65 | p =.10 | .01 | −.07 | .16 |
| Baseline GAF | −.27 | .03 | 9.21 | p < .001 | −.32 | −.21 | .87 |
| Early alliance | −.23 | .03 | 7.48 | p <.001 | −.29 | −.17 | .71 |
| Early symptom change | .21 | .03 | 6.37 | p <.001 | −.14 | .28 | .60 |
| Treatment group | .93 | .46 | 2.05 | p =.04 | −1.79 | −.01 | .19 |
| Alliance X Treatment group | .12 | .04 | 2.88 | p = .004 | .04 | .21 | .27 |
Note:
1
Intercept reflects estimated mean HAM-D score across all time points.
Gender reference group = male. Treatment group reference group = CBASP + ADM. GAF = Global Assessment of Functioning.